Description

Sotrovimab

Sotrovimab is a monoclonal antibody therapy used to treat COVID-19. It targets the spike protein of the  SARSCoV-2 virus, reducing its ability to infect cells. It’s given as a single intravenous dose to individuals with mild to moderate COVID-19 who are at high risk of developing severe illness. Sotrovimab has shown promising results in reducing the risk of hospitalization or death in high-risk individuals.Sotrovimab

Mechanism of Action

Sotrovimab targets the SARS-CoV-2 spike protein, which the virus uses to enter and infect human cells. By binding to the spike protein, sotrovimab prevents the virus from attaching to and entering the cells, thereby inhibiting its replication and spread.

Clinical Trials

 One Phase 3 clinical trial conducted in the United Kingdom (UK) found that sotrovimab reduced the risk of hospitalization or death in individuals with mild to moderate COVID-19 who were at high risk of progression to severe disease.

Another Phase 3 clinical trial conducted in the United States (US) found that sotrovimab reduced the risk of hospitalization or death in individuals with mild to moderate COVID-19 who were at high risk of hospitalization.

Approval and Authorization

 The authorization was based on evidence from the Phase 3 clinical trials mentioned above.

Administration and Dosage

The recommended dosage is a single dose of 500 mg or 1,000 mg, depending on the body weight of the patient.

Side Effects

 These side effects may include mild to moderate infusion-related reactions, such as itching, rash, and headache.

Conclusion

Sotrovimab is a novel monoclonal antibody therapeutic that has shown promise in the treatment of COVID-19. Its approval by the FDA is based on evidence from rigorous clinical trials, and its administration has shown to be generally safe.